Sugi Predict

Sugi Predict / Compounds / SCHEMBL1197014

SCHEMBL1197014

SCHEMBL1197014

O=C(O)Cc1c[c]ccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 2/20 0.58
▸ NAPRT Q6XQN6 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ ABCC4 O15439 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ CA2 P00918 1/20 0.43
▸ CAMK2A Q9UQM7 1/20 0.43
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ NSD2 O96028 1/20 0.40
▸ GRK2 P25098 1/20 0.40
▸ CASP6 P55212 1/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.40
▸ HPGD P15428 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10948644 0.96 AKR1B1 (0.54) AKR1B1NAPRTLMNAGAATSHR
SCHEMBL1195911 0.82 CA2 (0.45) AKR1B1LMNACA2CES2CES1
SCHEMBL27827127 0.82 ALDH1A1 (0.39) AKR1B1LMNATSHRCES2CES1
SCHEMBL1510167 0.81 GRIN2D (0.51) AKR1B1LMNAGAATSHRABCC4
SCHEMBL1419158 0.80 KEAP1 (0.61) CA2FFAR1MAPTKEAP1ALDH1A1
SCHEMBL1510273 0.80 LMNA (0.67) AKR1B1LMNAGAATSHRABCC4
SCHEMBL1570274 0.77 MEN1 (0.40) LMNAGAAPOLBHPGDKDM4E
SCHEMBL6316313 0.77 HDAC3 (0.63) LMNATSHRFFAR1HSD17B10MAPT
SCHEMBL2550859 0.77 PARP1 (0.38) POLBALDH1A1
SCHEMBL2642315 0.77 CYP4F2 (0.47) LMNAGAATSHRHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220251076-A1 Inhibitors of Beta-Hydoxylase for Treatment of Cancer MIDWESTERN UNIVERSITY 2022-08-11 — — US claimed
US-20210052561-A1 TARGETING ASPARTATE BETA-HYDROXYLASE SUPPRESSES TUMOR MALIGNANCY AND METASTASIS MIDWESTERN UNIVERSITY 2021-02-25 — — US claimed
US-20210032233-A1 Inhibitors of Beta-Hydroxylase for Treatment of Cancer MIDWESTERN UNIVERSITY 2021-02-04 — — US claimed
EP-3345596-B1 INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER RHODE ISLAND HOSPITAL (US) 2021-01-20 — — EP claimed
US-20200361925-A1 INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER RHODE ISLAND HOSPITAL (US) 2020-11-19 — — US claimed
US-10787445-B2 Inhibitors of beta-hydroxylase for treatment of cancer MIDWESTERN UNIVERSITY (US) 2020-09-29 — — US claimed
US-10710995-B2 Inhibitors of β-hydroxylase for treatment of cancer RHODE ISLAND HOSPITAL (US) 2020-07-14 — — US claimed
EP-3652174-A1 TAM KINASE INHIBITORS Syros Pharmaceuticals, Inc. (US) 2020-05-20 — — EP claimed
CN-110818660-A β -hydroxylase inhibitors for the treatment of cancer 罗得岛医院 2020-02-21 — — CN claimed
US-20190300519-A1 Inhibitors of Beta-Hydroxylase for Treatment of Cancer MIDWESTERN UNIVERSITY 2019-10-03 — — US claimed
WO-2000029377-A1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III F. HOFFMANN-LA ROCHE AG (CH) 2000-05-25 — — WO claimed
EP-0985660-A1 AMINOPHENOL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-03-15 — — EP claimed
US-5919824-A Aminophenol derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-07-06 — — US claimed
CN-1178523-A Aminophenol derivatives DIICHI PHARMACEUTICAL CO LTD (JP) 1998-04-08 — — CN claimed
US-5723480-A Adhesion receptor antagonists III MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1998-03-03 — — US claimed
US-5585376-A 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic activity GLAXO WELLCOME INC. (US) 1996-12-17 — — US claimed
US-5561148-A Adhesion receptor antagonists III MERCK PATENT GESELLSCHAFT MIT BESHRANKTER HAFTUNG (DE) 1996-10-01 — — US claimed
CN-1120845-A 1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity GLAXO INC (US) 1996-04-17 — — CN claimed
EP-0694040-A1 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY GLAXO WELLCOME INC. (US) 1996-01-31 — — EP claimed
WO-1994024151-A1 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY GLAXO INC. (US) 1994-10-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787445-B2 Inhibitors of beta-hydroxylase for treatment of cancer ASPH, CYP46A1, ALDH7A1 AKR1B1 13/4885NAPRT 856/4885LMNA 2397/4885
US-20210032233-A1 Inhibitors of Beta-Hydroxylase for Treatment of Cancer ASPH, CYP46A1, ALDH7A1 AKR1B1 13/4885NAPRT 856/4885LMNA 2397/4885
US-20210052561-A1 TARGETING ASPARTATE BETA-HYDROXYLASE SUPPRESSES TUMOR MALIGNANCY AND METASTASIS ASPH, GOT1, FOLH1 AKR1B1 93/4885NAPRT 723/4885LMNA 4443/4885
US-20220251076-A1 Inhibitors of Beta-Hydoxylase for Treatment of Cancer ASPH, HAGH, FAH AKR1B1 13/4885NAPRT 957/4885LMNA 2246/4885
US-20190300519-A1 Inhibitors of Beta-Hydroxylase for Treatment of Cancer ASPH, CYP46A1, ALDH7A1 AKR1B1 13/4885NAPRT 856/4885LMNA 2397/4885
US-10710995-B2 Inhibitors of β-hydroxylase for treatment of cancer ASPH, CYP46A1, AHR AKR1B1 10/4885NAPRT 851/4885LMNA 2362/4885
US-20200361925-A1 INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER ASPH, CYP46A1, ALDH7A1 AKR1B1 13/4885NAPRT 856/4885LMNA 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.